Applicant: Kunz et al. Attorney's Docket No.: 10527-1108006 / 03-216 US05

Serial No.: 09/910,388 Filed: July 20, 2001

Page : 2 of 7

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## Listing of Claims:

## 1-49. (Cancelled)

- 50. (Currently amended) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a therapeutic agent dispersed in a polymer matrix, wherein said cytostatic amount of said therapeutic agent inhibits a vascular smooth muscle cell activity without killing the cell, and wherein said therapeutic agent is a modified toxin, a TGF-beta production or activation stimulator, TGF-beta, tamoxifen, a nuclear enzyme DNA topoisomerase II inhibitor, a DNA polymerase inhibitor, an RNA polymerase inhibitor, an adenyl guanyl cyclase inhibitor, a superoxide dismutase inhibitor, a terminal deoxynucleotidyl-transferase, a reverse transcriptase, lovastatin, vinblastin, cytochalasins, taxol, taxotere, trichothecene, a modified diphtheria toxin, a modified ricin toxin, Pseudomonas exotoxin, a chemotactic factor inhibitor, a caffeic acid derivative, nilvadipine, a steroid hormone, sphingosine, somatostatin, or N-ethylmaleimide.
- 51. (Cancelled).
- 52. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

Applicant: Kunz et al. Attorney's Docket No.: 10527-1108006 / 03-216 US05

Serial No.: 09/910,388 Filed: July 20, 2001

Page : 3 of 7

53. (Previously presented) The method of claim 50, wherein the vascular surgical procedure

comprises angioplasty.

54. (Previously presented) The method of claim 50, wherein the locally administering

comprises administering the cytostatic amount of the therapeutic agent directly to vascular

smooth muscle tissue.

56-57. (Cancelled).

58. (Previously presented) The method of claim 50, wherein the therapeutic agent comprises

taxol or taxotere.

59. (Previously Presented) The method of claim 50, wherein the sustained release dosage

form is a microparticulate.

60-65. (Cancelled).